
-
Allovir Inc NasdaqCM:ALVR Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Location: 1100 Winter Street, Waltham, MA, 02451, United States | Website: https://www.allovir.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-69.08M
Cash
118.3M
Avg Qtr Burn
-16.93M
Short % of Float
6.75%
Insider Ownership
9.29%
Institutional Own.
13.66%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Posoleucel Details BK virus, Kidney transplantation | Phase 2 Update | |
ALVR106 Details Respiratory syncytial virus, Influenza, Human metapneumovirus, Parainfluenza virus | Failed Discontinued | |
Posoleucel Details Epstein-Barr virus, Human herpesvirus 6, BK virus, Adenovirus, Cytomegalovirus | Failed Discontinued | |
Posoleucel Details Virus-associated hemorrhagic cystitis , Adenovirus | Failed Discontinued | |
ALVR109 Details COVID-19 | Failed Discontinued |